Dingyao Hu - Cancer Hospital & Institute, Peking University

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 20 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

PI3K Inhibitor Idelalisib Enhances the Anti-Tumor Effects of CDK4/6 Inhibitor Palbociclib Via PLK1 in B-cell Lymphoma

Dingyao Hu,Jiaowu Cao, Hui Yu,Ning Ding,Lan Mi,Yingying Ye,Miaomiao Li,Dedao Wang, Jiajin Wu,Xiaogan Wang,Yuqin Song,Jun Zhu,Lingyan Ping

Cancer Letters (2024): 216996-216996

引用0浏览0WOS引用

The Mtor Kinase Inhibitor Everolimus Synergistically Enhances the Anti‐tumor Effect of the Janus Kinase 1 (JAK1) Inhibitor AZD4205 on Peripheral T Cell Lymphoma

Y. Ye, M. Wu,L. Mi,H. Yu,D. Wang,D. Hu,J. Cao,N. Ding,X. Wang,Y. Song, S. Shu, W. Zhang,J. Zhu

Hematological Oncologyno. S2 (2023): 558-559

引用0浏览0引用

Dynamic Single-Cell Profiling Reveals Novel Immune Regulatory Mechanism of ITK Inhibitor Soquelitinib in Refractory T Cell Lymphoma

Ning Ding,Yan Xie,Yong Guo, Kecheng Li,Tingting Du, Zhenjun Li, Yuejiao Li,Jiaowu Cao,Dingyao Hu,Lih-Yun Hsu,Richard Miller,Jun Zhu,Yuqin Song

Blood（2023）

引用0浏览0引用

Interleukin‐2‐inducible Kinase Represents a Novel Therapeutic Target for NK/T‐cell Lymphoma Treatment

J. Cao,D. Hu, H. Yu,M. Li, Y. Ye,D. Wang,J. Wu,L. Mi,S. Shu,H. Wu, X. Wang,M. Deng, C. Han,W. Zhang,N. Ding,Y. Xie,Y. Song,J. Zhu

Hematological Oncologyno. S2 (2023): 555-557

引用0浏览0引用

Itk Inhibitor Induces Th1 Skewing and Host Anti‐tumor Response Mediated by CD8+ TEMRA Cells in Refractory T Cell Lymphoma Patients

N. Ding,Y. Xie,R. Miller, S. Mahabhashyam, L. Hsu, Y. Guo,K. C. Li,T. Du,L. Mi,N. Lin,J. Cao,D. Hu,D. Wang,Y. Li, Z. Li,J. Zhu,Y. Song

Hematological Oncologyno. S2 (2023): 280-281

引用0浏览0引用

CRISPR/CAS9 SCREENING REVEALS SOS1 PARTICIPATE IN ASPARAGINASE RESISTANCE IN NK/T CELL LYMPHOMA

D. Wang, H. Wang,L. Mi,N. Ding, J. Cao, F. Feng,F. Qi,H. Yu,M. Li, Y. Ye,D. Hu,Y. Xie, H. Wu,Y. Song,J. Zhu

Hematological Oncologyno. S2 (2023): 801-803

引用0浏览0引用

Combination of CDK4/6 Inhibitor Palbociclib and PI3K Inhibitor Idelalisib Synergistically Induces an Anti-Tumor Effect in B-Cell Lymphoma and Overcomes Ibrutinib Resistance

Dingyao Hu,Jiaowu Cao,Dedao Wang, Jiajin Wu,Lan Mi,Lingyan Ping,Ning Ding,Yuqin Song,Jun Zhu

Bloodno. Supplement 1 (2023): 2826-2826

引用0浏览0引用

Ibrutinib Combined with Low-Dose HDAC Inhibitor Chidamide Synergistically Enhances the Anti-Tumor Effect in B-Cell Lymphoma

Hui Yu,Lan Mi,Weimin Zhang,Yingying Ye,Miaomiao Li,Dingyao Hu,Jiaowu Cao,Dedao Wang,Xiaogan Wang,Ning Ding,Yuqin Song,Jun Zhu

SSRN Electronic Journal（2022）

引用0浏览0WOS引用

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patients

Miaomiao Li,Lan Mi,Chunyang Wang,Xiaojuan Wang,Jianhua Zhu,Fei Qi, Hui Yu,Yingying Ye,Dedao Wang,Jiaowu Cao,Dingyao Hu,Quanyu Yang,Dandan Zhao,Tonghui Ma,Yuqin Song,Jun Zhu

Research Square (Research Square) (2022)

引用0浏览0引用

Clinical Implications of Circulating Tumor DNA in Predicting the Outcome of Diffuse Large B Cell Lymphoma Patients Receiving First-Line Therapy

Miaomiao Li,Lan Mi,Chunyang Wang,Xiaojuan Wang,Jianhua Zhu,Fei Qi,Hui Yu,Yingying Ye,Dedao Wang,Jiaowu Cao,Dingyao Hu,Quanyu Yang,Dandan Zhao,Tonghui Ma,Yuqin Song,Jun Zhu

BMC medicine（2022）

引用2浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn